 Hey guys, how you doing? This is Rich from Rich TV Live and richpixdaily.com and I have some breaking news for you today. That's right, from Trip Therapeutics, only here on Rich TV Live. And if you guys wanna learn the news, all you gotta do is go and subscribe to Rich TV Live on YouTube and go to richpixdaily.com where you too can join the trading community absolutely free or for a VIP membership, you get access to so much education and rewards and picks like Trip Therapeutics where we believe have enormous upside potential. Now let's talk about the news that is breaking right now. Trip Therapeutics submits IND application for phase two A clinical trial in eating disorders. That's right, Trip Therapeutics, TRYP in Canada as you see in the sign, TRYPF in America on the OTCQB exchange. A pharmaceutical company focused on developing psilocybin based compounds for disease with unmet medical needs announced today that it has submitted an investigational new drug IND application to the US Food and Drug Administration FDA to evaluate its clinical candidate, Trip TRP-8802 in a phase two A study for the treatment of patients with eating disorders. The trial is being conducted with Jennifer Miller, MD from the University of Florida and will evaluate the company's oral formulation of synthetic psilocybin Trip-8802 in combination with psychotherapy. Told you guys, I love psychedelics. This is just the beginning for psychedelics. They do not even have FDA approval and I believe that the upside is tremendous. The IND application represents a critical step in the drug development process for determining the effectiveness of TRYP-8802 for overeating disorders. TRYP expects to initiate phase two A study in Q4 of this year, which is pretty much right now subject to a favorable review of the IND by the FDA. We are walking in to Q4 as we speak. The submission of this IND represents hundreds of hours of collaborative preparation, design and coordination between TRYP and the team at the University of Florida as we pursue a leading edge treatment of psilocybin with psychotherapy, comment to Dr. Miller. I have thoroughly enjoyed working with the team at TRYP and our shared commitment to exploring new treatments for our patients who have so few existing therapies available to them because this is still the early days for psychedelics. The phase two clinical trial is expected to enroll 10 patients and various overeating disorders, including binge eating disorder, hypothalomatic obesity and Prater-Willi syndrome. The administration of psilocybin is reported in the literature to increase neuroplasticity leading to newly formed neural networks which may improve eating behavior. Patients will meet with psychotherapists who have been trained by fluence for two sessions prior to the administration of TRYP 8802, which will take place in two drug dosing sessions. Integration sessions with the psychotherapists will be conducted after the administration of the drug. This IND submission marks the most important milestone the company has achieved to date and will be critical in identifying patients' responses to TRYP 8802. The results from this study will also provide critical information to support our proprietary drug candidate TRYP 8803 that will be used in phase two B trials and beyond, commented Greg McKee, chairman and executive officer of TRYP. This is the first of several IND filings we expect to make in the coming months in support of our work to address various chronic pain and eating disorder indications. And we are eager to begin enrolling our first patients in multiple phase two A trials later this year. About TRYP therapeutics, and I think guys, I'm gonna show you guys the chart that we're right at the bottom here. TRYP therapeutics is a pharmaceutical company focused on developing psilocybin-based compounds for the treatment of diseases with unmet medical needs through accelerated regulatory pathways. TRYP psilocybin for neuro-psychiatric disorders, PFN, programs is focused on the development and synthetic psilocybin as a new class of drug for the treatment of chronic pain and other indications. The company has announced upcoming phase two A clinical trials with the University of Michigan and the University of Florida to evaluate its drug products for fibromyalgia and overeating disorders respectively. TRYP is also developing a proprietary psilocybin-based product, TRYP 8803 that uses a novel formulation and route administration to improve the patient experience. Big news, breaking news for TRYP therapeutics who has now submitted IND application for phase two A clinical trial in eating disorders. Now I wanna show you guys what I see here with this company. Early stage psychedelics company, this is a company that is a medicinal company. It is, I believe, going to be groundbreaking technology for potentially for eating disorders and other pain. And you can see here the market cap, I love the market cap, only a 24 million market cap. That's a baby market cap and only 66 million shares. So a very tight share structure. So I'm very impressed with the share structure. The website right here I'm gonna show you guys is triptherapeutics.com. You can see, you can subscribe right here. I'm gonna subscribe for their updates, just hit subscribe. And then you get put on their mailing list, just like that, which I've done. Oh, look, it says right here. You've already subscribed to trip therapeutics. So I'm already in there. So no need for me to subscribe again. I am already a subscriber, okay? This is their website. I'm not gonna go through the website right now, but you can see pretty cool website has everything you need on it right here. You can see their Twitter page, their LinkedIn page, their US symbol, their Canadian symbol, home, leadership, pipeline, investor information, news and contact. All of that is there. Triptherapeutics is leading the next wave of psychedelic drug development beyond mental health. And I'm telling you guys, this is a new era for psilocybin and companies like Trip are leading the charge. So tight share structure, big breaking news, working on FDA approval. And let's take a look at the stock in the share price. So you can see that they've been as high as $1.20 and that to me is kind of a sign of what's to come. Okay, so they're kind of showing their hand. If the company is successful, maybe we see them go back to $1.20. Well, the low low is 35 cents and we're currently sitting at 36. So we're the lowest pretty much it's ever been, okay? Despite the fact that it is a growing company and it's got big breaking news. So as a trader, you need to be aware that it's closer to the bottom than it is to the top. I don't think the downside pressure or I don't believe that there should be as much downward pressure from these prices onward but you never know. Always remember that Rich TV Live is strictly for information education purposes. Past performance is not an indication of future results. So just like this has come down, doesn't mean that it will continue to go down but it also doesn't mean that it can't go up. So we've seen it go as high as $1.20 before. It's currently at 35. Where do you think it goes in the future? Love to know what you guys think. That's why we do these videos. We bring you the news. We break down the deals. We break down the share structures so we can as a community come to a consensus and make good investing decisions. Let me know, what do you guys think about trip therapeutics? Do you like it? Do you like the psychedelic sector? Do you believe in it long-term? We know that these companies are still pre-revenue. So there's still some time before they really get robust as far as revenue but that's really the opportunity of an investor to try to get in for the win when the company's undervalued, underappreciated and underexposed based on this news, based on the chart analysis, based on the share structure and everything I've been researching on trip therapeutics. You can see right here, a company that is a new era for psilocybin. We are revolutionizing what psilocybin-based treatments can do with life-changing therapies for chronic pain and other indications. Fibromyalgia, phantom limb pain, complex regional pain syndrome, CRPS, binge eating disorder and hypothermatic obesity. Some of the areas of focus for trip therapeutics. Let me know what you guys think. Comment on the video. If you like these videos, please smash the like button. Comment down below. Share the video everywhere and subscribe. If you're alive, TRYPF in America, TRYP trip therapeutics in Canada. This is their Twitter page where you can follow them on Twitter. You can see I'm currently following. Can hit this bell for notifications. So every time they have any news, I get access to it right away. And let's see if we can follow them also on LinkedIn. This is their LinkedIn page. I believe I am following them already on LinkedIn. You can see I am already following on LinkedIn. That's the LinkedIn page. So we went through the news and let's just touch base on it real quickly again. TRYP Therapeutics submits IND application for phase two, a clinical trial in eating disorders. Zero bar rich, we wish to be live. And richpakesdaily.com. Bring in the news and we bring it to you first. Let me know what you guys think. It's your bar rich and I'm out. You're not winning. You're not watching. Bring in the winners and we bring them to you first. Thanks guys. We'll talk to you soon.